Direxion Daily S&P Biotech Bear 3X ETF
LABD
13 hedge funds and large institutions have $8.45M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2017 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
227% more call options, than puts
Call options by funds: $2.1M | Put options by funds: $642K
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
15% more capital invested
Capital invested by funds: $7.33M → $8.45M (+$1.12M)
0% less ownership
Funds ownership: 0.01% → 0% (-0%)
7% less funds holding
Funds holding: 14 → 13 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$1.85M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.38M |
| 3 |
VF
Virtu Financial
New York
|
+$1.38M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$914K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$692K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$692K |
| 2 |
Jane Street
New York
|
-$420K |
| 3 |
HF
HRT Financial
New York
|
-$340K |
| 4 |
FTUS
Flow Traders U.S.
New York
|
-$154K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$98.9K |
LABD Hedge Fund Activity: Q1 2017 in Review
13 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q1 2017, worth a combined $8.45M — up 15% from $7.33M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of LABD and 3 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 5 added.
The largest buyer was Credit Suisse, opening a new position worth an estimated $1.85M. The largest seller was Virtu KCG Holdings, cutting an estimated $692K.
- 13 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q1 2017, down from 14 in Q4 2016.
- Funds reported $8.45M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q1 2017, up 15% quarter-over-quarter.
- 3 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q1 2017 and 4 closed out, a net change of -1 holder.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q1 2017 was Credit Suisse, an estimated $1.85M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q1 2017 was Virtu KCG Holdings, an estimated $692K sold.
Based on aggregated 13F filings for Q1 2017.